Reply to: "Sorafenib efficacy for treatment of HCC recurrence after liver transplantation is an open issue".
The Hepato-Oncology Group, Gastro-Intestinal Surgery, Liver Transplantation and Hepatology - Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133 Milan, Italy.
Carlo
C
Sposito
The Hepato-Oncology Group, Gastro-Intestinal Surgery, Liver Transplantation and Hepatology - Fondazione IRCCS Istituto Nazionale Tumori, via Venezian 1, 20133 Milan, Italy. Electronic address: vincenzo.mazzaferro@istitutotumori.mi.it.
Vincenzo
V
Mazzaferro
D006528:Carcinoma, Hepatocellular / Q000628:therapy*; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000628:therapy*; D016031:Liver Transplantation; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000628:therapy*; D009536:Niacinamide / Q000031:analogs & derivatives*; D010671:Phenylurea Compounds / Q000627:therapeutic use*
D010671:Phenylurea Compounds; D009536:Niacinamide